Trial Profile
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) - SELECT - PsA 2
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT - PsA 2
- Sponsors AbbVie; AbbVie Germany
- 15 Nov 2023 Results of post hoc analysis (n=423) assessing site-specific responses of enthesitis and dactylitis to treatment with UPA over 56 weeks in patients with PsA presented at the ACR Convergence 2023
- 15 Nov 2023 Results of post hoc analysis assessing the achievement of goals according to these measures in pts with PsA following long-term treatment with upadacitinib (UPA), an oral JAK inhibitor, at week (wk) 152 from two phase 3 trials(SELECT-PsA 1 and SELECT-PsA 2), presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of post hoc analysis evaluating long-term efficacy of UPA in patients with PsA and involvement in 1 or more regions of weight-bearing joints from SELECT-PsA 1 and SELECT-PsA 2 trials, presented at the ACR Convergence 2023.